lsh semaglutide Improves Hidradenitis Suppurativa in Patients With Obesity Semaglutide

Iron bisglycinate chelate (18mg, 100% DV) chelated for absorption, gentle on the stomach

Lose weight with Tirzepatide, a powerful dual GLP-1/GIP therapy proven to support appetite control and fat loss

Note: Anti-Obesity GLP-1s Wegovy and Zepbound, Anti-Diabetes GLP-1s Ozempic and Mounjaro Source: IQVIA MAAS Patient Behavior Library Tool

Free retatrutide reconstitution and dosage calculator

With weekly injections, patients average 10.9% weight loss in six months

Leading Players in the GLP-1 Market Novo Nordisk 38.72% Ozempic Wegovy Rybelsus Eli Lilly 28.41% Mounjaro Zepbound Sanofi 8.76% 4 AstraZeneca 6.62% 5 GSK 4.95% 6 Regeneron 3.27% 7 Pfizer 2.61% 8 Amgen 1.98% 9 Sun Pharma 1.52% Boehringer Ingelheim 1.24% Together, Novo Nordisk and Eli Lilly account for more than 67% of the market, highlighting the intense competition between the two companies that currently lead the obesity and diabetes treatment revolution